DK0922034T3 - Tetrahydroquinolinderivater som EAA-antagonister - Google Patents

Tetrahydroquinolinderivater som EAA-antagonister

Info

Publication number
DK0922034T3
DK0922034T3 DK97943809T DK97943809T DK0922034T3 DK 0922034 T3 DK0922034 T3 DK 0922034T3 DK 97943809 T DK97943809 T DK 97943809T DK 97943809 T DK97943809 T DK 97943809T DK 0922034 T3 DK0922034 T3 DK 0922034T3
Authority
DK
Denmark
Prior art keywords
tetrahydroquinoline derivatives
eaa antagonists
eaa
antagonists
tetrahydroquinoline
Prior art date
Application number
DK97943809T
Other languages
Danish (da)
English (en)
Inventor
Fabio Maria Sabbatini
Romano Di-Fabio
Alessandra Pasquarello
Original Assignee
Glaxosmithkline Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Spa filed Critical Glaxosmithkline Spa
Application granted granted Critical
Publication of DK0922034T3 publication Critical patent/DK0922034T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK97943809T 1996-08-17 1997-08-14 Tetrahydroquinolinderivater som EAA-antagonister DK0922034T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9617305.9A GB9617305D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds
PCT/EP1997/004440 WO1998007704A1 (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists

Publications (1)

Publication Number Publication Date
DK0922034T3 true DK0922034T3 (da) 2002-11-18

Family

ID=10798623

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97943809T DK0922034T3 (da) 1996-08-17 1997-08-14 Tetrahydroquinolinderivater som EAA-antagonister

Country Status (34)

Country Link
US (1) US6479488B1 (cs)
EP (1) EP0922034B1 (cs)
JP (1) JP4108129B2 (cs)
KR (1) KR100552864B1 (cs)
CN (1) CN1131214C (cs)
AP (1) AP877A (cs)
AR (1) AR008296A1 (cs)
AT (1) ATE221052T1 (cs)
AU (1) AU724473B2 (cs)
BR (1) BR9711311B1 (cs)
CA (1) CA2264118C (cs)
CO (1) CO4900066A1 (cs)
CZ (1) CZ296250B6 (cs)
DE (1) DE69714265T2 (cs)
DK (1) DK0922034T3 (cs)
EA (1) EA001704B1 (cs)
ES (1) ES2181030T3 (cs)
GB (1) GB9617305D0 (cs)
HU (1) HU225797B1 (cs)
ID (1) ID18095A (cs)
IL (1) IL128141A0 (cs)
IS (1) IS4953A (cs)
MY (1) MY116952A (cs)
NO (1) NO312241B1 (cs)
NZ (1) NZ333812A (cs)
PE (1) PE107098A1 (cs)
PL (1) PL194532B1 (cs)
PT (1) PT922034E (cs)
SI (1) SI0922034T1 (cs)
TR (1) TR199900336T2 (cs)
TW (1) TW449582B (cs)
WO (1) WO1998007704A1 (cs)
YU (1) YU6799A (cs)
ZA (1) ZA977326B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
AU2002359875B2 (en) * 2001-12-28 2009-01-08 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
WO2004073639A2 (en) * 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
BRPI0417749A (pt) * 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
BRPI0509524A (pt) * 2004-04-01 2007-09-18 Acadia Pharm Inc formas cristalinas de n-desmetilclozapina
JP4754566B2 (ja) 2005-07-22 2011-08-24 持田製薬株式会社 新規なヘテロシクリデンアセトアミド誘導体
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
AU2006291134C1 (en) 2005-09-12 2013-08-15 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
US9855212B2 (en) 2009-10-30 2018-01-02 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases
AU2012321345B2 (en) 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL93610A0 (en) * 1989-03-08 1990-12-23 Merck Sharp & Dohme Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
CZ292379B6 (cs) * 1995-09-29 2003-09-17 Glaxo Wellcome Spa Tetrahydrochinolinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem

Also Published As

Publication number Publication date
EA199900121A1 (ru) 1999-10-28
EA001704B1 (ru) 2001-06-25
IL128141A0 (en) 1999-11-30
ID18095A (id) 1998-02-26
GB9617305D0 (en) 1996-09-25
CZ52999A3 (cs) 1999-07-14
AU4551897A (en) 1998-03-06
BR9711311A (pt) 1999-08-17
AR008296A1 (es) 1999-12-29
JP4108129B2 (ja) 2008-06-25
CO4900066A1 (es) 2000-03-27
SI0922034T1 (en) 2003-02-28
CZ296250B6 (cs) 2006-02-15
KR20000068172A (ko) 2000-11-25
BR9711311B1 (pt) 2009-01-13
JP2001508031A (ja) 2001-06-19
EP0922034A1 (en) 1999-06-16
MY116952A (en) 2004-04-30
PL331562A1 (en) 1999-07-19
PL194532B1 (pl) 2007-06-29
CA2264118A1 (en) 1998-02-26
AP877A (en) 2000-09-27
ZA977326B (en) 1999-02-15
KR100552864B1 (ko) 2006-02-20
CA2264118C (en) 2008-06-17
ES2181030T3 (es) 2003-02-16
NO990723D0 (no) 1999-02-16
PE107098A1 (es) 1999-01-15
IS4953A (is) 1999-01-22
CN1227544A (zh) 1999-09-01
PT922034E (pt) 2002-12-31
TW449582B (en) 2001-08-11
NO990723L (no) 1999-04-14
NO312241B1 (no) 2002-04-15
YU6799A (sh) 2000-03-21
EP0922034B1 (en) 2002-07-24
HU225797B1 (en) 2007-09-28
HUP9903108A3 (en) 2004-04-28
TR199900336T2 (xx) 1999-04-21
AP9901459A0 (en) 1999-03-31
ATE221052T1 (de) 2002-08-15
CN1131214C (zh) 2003-12-17
DE69714265D1 (de) 2002-08-29
DE69714265T2 (de) 2003-03-06
US6479488B1 (en) 2002-11-12
AU724473B2 (en) 2000-09-21
NZ333812A (en) 2000-07-28
WO1998007704A1 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
NO990723L (no) Tetrahydrokinolinderivater som EAA antagonister
NO20013003D0 (no) Kinolin-derivater
ATE228505T1 (de) Chinolinderivate
ATE250036T1 (de) Chinolinderivate
NO965036L (no) Kinolinderivater som techykinin NK3 reseptor-antagonister
ATE236155T1 (de) Naphthyridin-derivate
DK1140935T3 (da) 1,2-anellerede quinolinderivater
IS1902B (is) Nýjar 19-nor-pregnene afleiður
ATE229005T1 (de) Chinolinderivate
NO991384D0 (no) Substituerte heterocykler som anti-tumormidler
NO974043D0 (no) Indolderivater som EAA-antagonister
ATE255098T1 (de) Substituierte chromanderivate
NO991560D0 (no) PDE IV som inhiberer 2-cyanoiminoimidazol-derivater
ATE255099T1 (de) Substituierte chromanderivate
DK0854867T3 (da) Tetrahydroquinoliner som NMDA-antagonister
DK1086093T3 (da) Tetrahydroquinolinderivater som glycinantagonister
FI954614L (fi) Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina
PT931087E (pt) Novos derivados de piranosido
FI970143A0 (fi) Kinoliinijohdannaiset leukotrieeniantagonisteina
HK1018452A (en) Tetrahydroquinoline derivatives as eaa antagonists
SK2042U (sk) Balkón
ATA73396A (de) 3-methylimino-3-cephemderivate 3-methylimino-3-cephemderivate
ATA69896A (de) 3-methylimino-3-cephemderivate 3-methylimino-3-cephemderivate